


Stem cells are revolutionizing the treatment of incurable diseases
Potential
Naïve stem cells can dynamically adapt to their surrounding tissues and influence the cellular microenvironment, giving them the potential to treat, attenuate, or halt the progression of complex, multifactorial, and chronic diseases.
Problem
Current therapies have limitations of efficacy, scalability and cost.
Opportunity
Based on the discovery of hOMSC by Prof. Pitaru at Tel-Aviv University, Cytora leveraged hOMSC as a unique naïve stem cell population with inherent neural properties to develop effective, safe, and scalable off-the-shelf products for chronic and neurodegenerative diseases.

Harnessing the Power of hOMSC
Taking origin from the embryonic brain, hOMSC retain properties of neural crest stem cells capable of supporting neural tissues and influencing neurodegenerative disease processes. hOMSC integrate within the affected tissue and remain functional for a few months.
Cytora’s products have special abilities to treat hard-to-heal diabetic wounds such as Diabetic Foot Ulcer (DFU), and Neurodegenerative diseases such as Multiple System Atrophy (MSA), Parkinson’s Disease, Alzheimer’s Disease and autoimmune diseases.



The Ultra Potent Neural Crest Stem Cells


High expandability
A tiny biopsy of 4x3x2 mm hOMSC from a healthy donor generates therapeutic doses for thousands of sick people, a prerequisite for the production of large batches for “off-the-shelf” products.


Robust, efficient and cost-effective expandability
A simple culture medium with a simple production process produces comparable results across donors, irrespective of age or gender.
Robust GMP production line capable of producing therapeutic doses for thousands of patients.


Allogeneic immune properties
Naïve allogeneic hOMSC do not trigger cellular or humoral immune responses upon transplantation. Therefore, hOMSC can be suitable for use as allogeneic "off-the-shelf" products.


Potency & safety - a unique combination

hOMSC combine the high potency of primitive stem cells combined with a high safety profile of adult stem cells (non-tumorigenic, non-immunogenic).